SCHEMBL91590

SCHEMBL91590

Cc1ccc(NC(=O)c2nn(C)c3ccccc23)c(C)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
MAPT P10636 3/20 0.55
HPGD P15428 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
LCK P06239 1/20 0.55
CSK P41240 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
KDM4E B2RXH2 1/20 0.55
ELANE P08246 2/20 0.48
GAA P10253 2/20 0.48
ATM Q13315 1/20 0.48
RAB9A P51151 4/20 0.48
NPC1 O15118 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
LMNA P02545 2/20 0.47
POLB P06746 1/20 0.47
HTT P42858 1/20 0.47
CYP3A4 P08684 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL91600 0.88 SMN1; SMN2 (0.55) ALDH1A1MAPTHPGDSMN1; SMN2LCK
SCHEMBL10273937 0.88 THRB (0.56) ALDH1A1MAPTLCKCSKKDM4E
SCHEMBL91595 0.87 KDM4E (0.58) ALDH1A1LCKCSKKDM4EELANE
SCHEMBL91601 0.86 KDM4E (0.54) ALDH1A1MAPTHPGDLCKCSK
SCHEMBL14772008 0.85 KDM4E (0.50) ALDH1A1MAPTHPGDSMN1; SMN2LCK
SCHEMBL91588 0.83 KDM4E (0.53) ALDH1A1LCKCSKKDM4EELANE
SCHEMBL92358 0.81 KDM4E (0.53) ALDH1A1LCKCSKKDM4EELANE
SCHEMBL92552 0.81 KDM4E (0.53) ALDH1A1LCKCSKKDM4EELANE
SCHEMBL24004611 0.78 KDM4E (0.59) ALDH1A1MAPTHPGDNPSR1KDM4E
SCHEMBL14772007 0.78 KDM4E (0.50) ALDH1A1LCKCSKKDM4EELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 ALDH1A1 216/4885MAPT 4775/4885HPGD 1752/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 ALDH1A1 207/4885MAPT 4773/4885HPGD 1734/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 ALDH1A1 525/4885MAPT 4795/4885HPGD 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.